Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin

Krystal Biotech, Inc. (NASDAQ:KRYS) reported preliminary clinical findings from a pilot study of KB113, an investigational intratumoral immunotherapy being developed for patients with Gorlin syndrome, showing regression in more than 80% of assessed basal cell carcinoma (BCC) lesions.